Verified source report
STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program
The "triple-G" weight loss drug, Pfizer's lung cancer trial results, and more biotech news from The Readout
coverage / Source report
What happened
According to STAT’s source item, STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program, The “triple-G” weight loss drug, Pfizer’s lung cancer trial results, and more biotech news from The Readout
Context
The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-06-23T13:06:24+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.
Source links
- STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ programSTAT - 2026-06-23T13:06:24+00:00
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.